Press Releases

Date Title and Summary Additional Formats
Toggle Summary Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-Modified Dextromethorphan for Disorders of the Nervous System
Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-Modified Dextromethorphan for Disorders of the Nervous System Aliso Viejo, CA and Lexington, MA – Avanir Pharmaceuticals, Inc. (Nasdaq: AVNR) and Concert Pharmaceuticals, Inc.
View HTML
Toggle Summary Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDQ: CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the clinical progression of AVP-786.
View HTML
Toggle Summary Concert Pharmaceuticals Achieves $2 Million Milestone from Avanir Pharmaceuticals for Phase 3 Initiation of AVP-786 for Agitation in Patients with Alzheimer's Disease
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the progression of the clinical development of AVP-786.
View HTML
Toggle Summary Concert Pharmaceuticals Advances Novel Chronic Kidney Disease Treatment, CTP-499, in Phase 1 Clinical Study; First-in-Class Drug Candidate from Deuterium Platform Has Anti-Inflammatory, Anti-Fibrotic, and Anti-Oxidant Properties
First-in-Class Drug Candidate from Deuterium Platform Has Anti-Inflammatory, Anti-Fibrotic, and Anti-Oxidant Properties
View HTML
Toggle Summary Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata
Company On Track to Report Topline Data from the 4 mg and 8 mg Twice-Daily Cohorts in Fourth Quarter of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)--Sep. 26, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will include an additional cohort of patients in the Phase 2a trial
View HTML
Toggle Summary Concert Pharmaceuticals and Fast Forward Announce Collaboration to Advance Novel Treatment for Spasticity and Pain in Multiple Sclerosis
Concert Pharmaceuticals and Fast Forward Announce Collaboration to Advance Novel Treatment for Spasticity and Pain in Multiple Sclerosis Lexington, MA and New York, NY – Concert Pharmaceuticals, Inc. and Fast Forward, LLC, the National Multiple Sclerosis Society’s subsidiary devoted to bridging the
View HTML
Toggle Summary Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs
Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs LEXINGTON, Mass and London -- Concert Pharmaceuticals and GlaxoSmithKline (NYSE: GSK) announced
View HTML
Toggle Summary Concert Pharmaceuticals Announces $30 Million Venture Debt Financing from Hercules Capital
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into a $30.0 million venture debt financing agreement with Hercules Capital, Inc. "This non-dilutive financing further extends our existing cash runway.
View HTML
Toggle Summary Concert Pharmaceuticals Announces $8 Million Milestone from Celgene
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has achieved an $8 million milestone under its development and license agreement with Celgene Corporation (NASDAQ: CELG) for completion of the Phase 1 clinical evaluation of CTP-730.
View HTML
Toggle Summary Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate in Schizophrenia
CTP-692 Poised to Enter Clinical Development in 2018 as an Adjunctive Treatment of Schizophrenia Conference Call Scheduled Tomorrow at 8:30 a.m. ET for Company Update and 2017 Financial Results LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 28, 2018-- Concert Pharmaceuticals, Inc.
View HTML